Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA requests $4.3 billion for key device initiatives in FY 2012

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration has requested a budget of $4.3 billion for fiscal year 2012, which covers the period of 1 October 2011 through 30 September 20121. The increased funds will be used for, among other things, training the FDA staff to effectively review and use third-party International Organization for Standardization (ISO) audits of foreign device manufacturing facilities for compliance2.

You may also be interested in...



Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

Global Pharma Guidance Tracker – March 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

UsernamePublicRestriction

Register

SC096538

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel